RxDoctor Payments DataLook up a doctor →

Ronald Barebo, MD

Neurology · Huntington, WVNPI 1922033026

Payments from drug & device makers

$28,437in general payments, 2019–2025

Across 747 payments — averaging $38.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Novo Nordisk$932
  • Biogen$766
  • AstraZeneca$684
  • E.r. Squibb & Sons, L.L.C.$564
  • Amgen$536
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$15,56055%
  • Travel & lodging$4782%
  • Food & beverage$12,36343%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)167$18,726
Novo Nordisk71$932
Biogen34$766
AstraZeneca(2 entities)38$684
E.r. Squibb & Sons, L.L.C.26$564
Amgen46$536
Johnson & Johnson(2 entities)31$430
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC29$361
Neurelis, Inc.3$329
Boehringer Ingelheim24$326
Paratek Pharmaceuticals, Inc.18$320
Lilly USA, LLC16$307
Argenx US, Inc.18$268
Novartis12$265
Bayer13$251
Otsuka America Pharmaceutical, Inc.17$248
Teva Pharmaceuticals USA, Inc.17$244
Avanir Pharmaceuticals, Inc.19$240
Vifor Pharma, Inc.17$212
Lundbeck LLC6$193
Amarin Pharma, Inc.11$156
Biohaven Pharmaceuticals, Inc.8$139
Esperion Therapeutics, Inc.8$126
Takeda Pharmaceuticals U.S.A., Inc.9$125
Supernus Pharmaceuticals, Inc.9$123
Neurocrine Biosciences, Inc.7$123
Chiesi USA, Inc.6$122
Biohaven Pharmaceutical Holding Company Ltd.6$113
Adamas Pharmaceuticals, Inc.1$105
Pfizer6$102
Daiichi Sankyo Inc.5$98
Mallinckrodt Enterprises LLC1$67
Boston Scientific4$66
Intercept Pharmaceuticals, Inc.4$60
Shield Therapeutics Inc2$54
Genentech USA, Inc.4$52
Sunovion Pharmaceuticals Inc.3$49
Abbott2$47
Xeris Pharmaceuticals, Inc.2$39
Scilex Pharmaceuticals Inc.2$38
Endo Pharmaceuticals Inc.2$34
Strongbridge US Inc.2$28
Phathom Pharmaceuticals, Inc.2$28
Aurinia Pharma U.S., Inc.1$28
Corcept Therapeutics2$26
Otsuka Pharmaceutical Development & Commercialization, Inc.1$25
Mylan Specialty L.p.1$24
Philips North America LLC1$23
Sanofi-aventis U.S. LLC1$23
Insulet Corporation1$21
Baxter Healthcare1$21
Scpharmaceuticals Inc.1$19
Merck1$18
Kowa Pharmaceuticals America, Inc.1$17
Organon1$16
Shire North American Group Inc1$14
GSK1$14
Eisai Inc.1$14
Smith+Nephew1$13
Therapeuticsmd, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,437 in reported general payments places this provider in the 85th percentile of 93 neurology providers in West Virginia.

See all neurology providers in West Virginia

Medicare billing

Part B allowed, 2024
$283,964
Medicare patients
925
Services billed
4,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant29$28,212
QuliptaAtogepant17$16,646
Emgality PenGalcanezumab-Gnlm16$16,317
Carbamazepine ErCarbamazepine51$8,083
Levetiracetam180$6,704
Carbamazepine85$6,009
Lacosamide40$4,610
Aspirin-Dipyridamole ErAspirin/Dipyridamole17$4,520
AmantadineAmantadine Hcl43$4,188
Rivastigmine29$4,022
Memantine Hcl151$3,839
Gabapentin243$3,513
Carbidopa-LevodopaCarbidopa/Levodopa116$3,242
Primidone126$2,516
Pyridostigmine Bromide33$2,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$18,726$44,85846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 neurology providers in West Virginia.

Other neurology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →